JAK2 and acute myeloid leukemia: We previously reported that the JAK2-V617F oncogenic mutation enhances the expression of the immunosuppressive programmed death-ligand 1 (PD-L1) (29) and sought to investigate connections between oncogenes found in AML and the expression of TIM-3 (encoded by the hepatitis A virus cellular receptor 2 [Havcr2] gene) and its ligands.